Optimization of systemic treatment strategies in elderly patients with advanced solid malignancies: OptiMal trial

Optimization of systemic treatment strategies in elderly patients with advanced solid malignancies: OptiMal trial - OptiMal

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47698

Enrollment

Registered

2013-07-02

Start date

2013-09-05

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer palliative chemotherapy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age >= 70 years; Diagnosis of advanced cancer of colorectum, breast, prostate, stomach or esophagus; Standard palliative treatment with cytotoxic agents will be started; Life expectancy >= 3 months; Able to give informed consent

Exclusion criteria

Exclusion criteria: Presence of cytopenia due to iron-,vitamin B12 and folic acid deficiency or hemolysis, unless adequately supplemented. GFR = 2,5 ULN, in case of liver metastases serum AST and ALT >= 5 x ULN

Design outcomes

Primary

Measure	Time frame
* Toxicity of treatment due to any cause * Prevalence of MDS/IDUS in the studied group of patients	—

Secondary

Measure	Time frame
• Prevalence of sarcopenia in the studied group of patients • (Termination, postponement or dose modification) of treatment due to any cause • Overall survival • Response to treatment • Progression free survival • Difference in combination therapy versus monotherapy • Quality of life	—

Countries

Netherlands

Outcome results